KELLY VENTURES LTD. The parties intend to complete a business combination or other similarly structured transaction which will constitute a reverse take-over of KKL. The Proposed Transaction is intended to be an arm's length Qualifying Transaction (the 'Qualifying Transaction') for the Company as defined under TSXV policies. Ebers is a Canadian registered Pharma Tech company, with a portfolio of patents and development methods for producing cocrystals. Ebers is strategically positioned at the nexus of the big pharmaceutical and cocrystal industries, enabling the Company to play a crucial role in the development of the next generation of pharmaceuticals and therapies, and to simultaneously exploit the rapidly advancing cannabinoid and psilocybin cocrystal, pharmaceutical and wellness areas. Of these, the most widely studied and used application is in drug development and more specifically, the formation, design, and implementation of active pharmaceutical ingredients ('API').
Contact:
Email: plarkin@pro.net
Forward-Looking Statements Disclaimer
Certain information in this press release may contain forward-looking statements. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict. Actual results might differ materially from results suggested in any forward-looking statements. KKL assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements unless and until required by securities laws applicable to KKL. Additional information identifying risks and uncertainties is contained in filings by KKL with the Canadian securities regulators, which filings are available at www.sedar.com. Completion of the Ebers Transaction is subject to a number of conditions, including but not limited to, TSXV acceptance and if applicable pursuant to TSXV requirements, majority of the minority shareholder approval. Where applicable, the transaction cannot close until the required shareholder approval is obtained. There can be no assurance that the transaction will be completed as proposed or at all. Investors are cautioned that, except as disclosed in the filing statement to be prepared in connection with the Ebers Transaction, any information released or received with respect to the transaction may not be accurate or complete and should not be relied upon. Trading in the securities of a capital pool company should be considered highly speculative.
(C) 2020 Electronic News Publishing, source
